Human leukocyte antigen class II transgenic mouse model unmasks the significant extrahepatic pathology in toxic shock syndrome

American Journal of Pathology

Volumn 178, Issue 6, 2011, Pages 2760-2773

  Tilahun, Ashenafi Y ^a   Marietta, Eric V ^b   Wu, Tsung Teh ^b   Patel, Robin ^b   David, Chella S ^a   Rajagopalan, Govindarajan ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATININE; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; HEART; IMMUNOFLUORESCENCE; IMMUNOPATHOGENESIS; INFLAMMATION; INTESTINE ABSORPTION; INTESTINE CELL; KIDNEY; LIVER; LIVER FAILURE; LUNG; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SMALL INTESTINE; T LYMPHOCYTE SUBPOPULATION; TOXIC SHOCK SYNDROME; TRANSGENIC MOUSE;

EID: 79959470588     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2011.02.033     Document Type: Article

References (69)

1. Brooks GF, Carroll KC, Butel JS, Morse SA (Eds): The staphylococci. Jawetz, Melnick, & Adelberg's Medical Microbiology, ed 25, ch 13. New York, The McGraw-Hill Companies, Inc., 2010
2. Manders SM: Toxin-mediated streptococcal and staphylococcal disease. J Am Acad Dermatol 1998, 39:383-398 (Pubitemid 28417372)
3. Fraser DJ, Proft T: The bacterial superantigen and superantigen-like proteins. Immunol Rev 2008, 225:226-243
4. Dinges MM, Orwin PM, Schlievert PM: Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 2000, 13:16-34 (Pubitemid 30039341)
5. Li H, Llera A, Malchiodi EL, Mariuzza RA: The structural basis of T cell activation by superantigens. Annu Rev Immunol 1999, 17:435-466 (Pubitemid 29241131)
6. Murray RJ: Recognition and management of Staphylococcus aureus toxin-mediated disease. Int Med J 2005, 35:S106-S119 (Pubitemid 44933544)
7. Lappin E, Ferguson AJ: Gram-positive toxic shock syndromes. Lancet Infect Dis 2009, 9:281-290
8. Schlievert PM: Staphylococcal toxic shock syndrome: still a problem. Med J Aust 2005, 182:651-652 (Pubitemid 40932339)
9. Schlievert PM, Strandberg KL, Lin Y-C, Peterson ML, Leung DYM: Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. J Allergy Clin Immunol 2010, 125:39-49
10. John CC, Niermann M, Sharon B, Peterson ML, Kranz DM, Schlievert PM: Staphylococcal toxic shock syndrome erythroderma is associated with superantigenicity and hypersensitivity. Clin Infect Dis 2009, 49:1893-1896
11. McCormick JK, Yarwood JM, Schlievert PM: Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001, 55:77-104 (Pubitemid 32978101)
12. Tang Y-W, Himmelfarb E, Wills M, Stratton CW: Characterization of three Staphylococcus aureus isolates from a 17-year-old female who died of tampon-related toxic shock syndrome. J Clin Microbiol 2010, 48:1974-1977
13. Klug CD, Keay CR, Ginde AA: Fatal toxic shock syndrome from an intrauterine device. Ann Emerg Med 2009, 54:701-703
14. Wasserzug O, Valinsky L, Klement E, Bar-Zeev Y, Davidovitch N, Orr N, Korenman Z, Kayouf R, Sela T, Ambar R, Derazne E, Dagan R, Zarka S: A cluster of ecthyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes. Clin Infect Dis 2009, 48:1213-1219
15. Honda H, Krauss MJ, Jones JC, Olsen MA, Warren DK: The value of infectious diseases consultation in Staphylococcus aureus bacteremia. Am J Med 2010, 123:631-637 [Epub ahead of press May 20, 2010]
16. Tang Y-W, Stratton CW: Staphylococcus aureus: an old pathogen with new weapons. Clin Lab Med 2010, 30:179-208
17. Abram AC, Bellian KT, Giles WJ, Gross CW: Toxic shock syndrome after functional endonasal sinus surgery: an all or none phenomenon?. Laryngoscope 1994, 104:927-931 (Pubitemid 24245057)
18. Pinna GS, Kafetzis DA, Tselkas OI, Skevaki CL: Kawasaki disease: an overview. Curr Opin Infect Dis 2008, 21:263-270 (Pubitemid 351620381)
19. Takahashi N, Nishida H, Kato H, Imanishi Ki, Sakata Y, Uchiyama T: Exanthematous disease induced by toxic shock syndrome toxin 1 in the early neonatal period. Lancet 1998, 351:1614-1619 (Pubitemid 28252177)
20. Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K-I, Oguchi A, Nagai Y, Iwama N, Asano K, Naimi T, Kuroda H, Cui L, Yamamoto K, Hiramatsu K: Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002, 359:1819-1827 (Pubitemid 34607058)
21. Gbaguidi-Haore H, Thouverez M, Couetdic G, Cholley P, Talon D, Bertrand X: Usefulness of antimicrobial resistance pattern for detecting PVL- or TSST-1-producing methicillin-resistant Staphylococcus aureus in a French university hospital. J Med Microbiol 2009, 58: 1337-1340
22. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, Cui L, Oguchi A, Aoki K-I, Nagai Y, Lian J, Ito T, Kanamori M, Matsumaru H, Maruyama A, Murakami H, Hosoyama A, Mizutani UY, Takahashi NK, Sawano T, Inoue R-I, Kaito C, Sekimizu K, Hirakawa H, Kuhara S, Goto S, Yabuzaki J, Kanehisa M, Yamashita A, Oshima K, Furuya K, Yoshino C, Shiba T, Hattori M, Ogasawara N, Hayashi H, Hiramatsu K: Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 2001, 357:1225-1240 (Pubitemid 32539050)
23. Madsen JM: Toxins as weapons of mass destruction: a comparison and contrast with biological-warfare and chemical-warfare agents. Clin Lab Med 2001, 21:593-605 (Pubitemid 32884149)
24. Ulrich R, Sidell S, Taylor TJ, Wilhelmsen CL, Franz DR: Staphylococcal Enterotoxin B and Related Pyrogenic Toxins. Edited by Zajtchuk R. Bethesda, MD, Office of the Surgeon General, Department of the Army, United States of America, 1997, pp 621-630
25. Kaul R, McGeer A, Norrby-Teglund A, Malak K, Schwartz B, O'Rourke K, Talbot J, Low DE; Canadian Streptococcal Study Group: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 1999, 28:800-807 (Pubitemid 29169419)
26. Stevens DL, Wallace RJ, Hamilton SM, Bryant AE: Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis 2006, 42:729-730 (Pubitemid 43271393)
27. Sugiyama H, McKissic EM Jr, Bergdoll MS, Heller B: Enhancement of Bacterial endotoxin lethality by staphylococcal enterotoxin. J Infect Dis 1964, 114:111-118
28. Schlievert PM, Schoettle DJ, Watson DW: Purification and physicochemical and biological characterization of a staphylococcal pyrogenic exotoxin. Infect Immun 1979, 23:609-617 (Pubitemid 9138960)
29. Buonpane RA, Churchill HRO, Moza B, Sundberg EJ, Peterson ML, Schlievert PM, Kranz DM: Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nature Med 2007, 13:725-729 (Pubitemid 46889753)
30. Dinges MM, Gregerson DS, Tripp TJ, McCormick JK, Schlievert PM: Effects of total body irradiation and cyclosporin A on the lethality of toxic shock syndrome toxin-1 in a rabbit model of toxic shock syndrome. J Infect Dis 2003, 188:1142-1145 (Pubitemid 37338978)
31. Lavoie PM, Thibodeau J, Erard F, Sekaly RP: Understanding the mechanism of action of bacterial superantigens from a decade of research. Immunol Rev 1999, 168:257-269 (Pubitemid 29276687)
32. Chen JY, Qiao Y, Komisar JL, Baze WB, Hsu IC, Tseng J: Increased susceptibility to staphylococcal enterotoxin B intoxication in mice primed with actinomycin D. Infect Immun 1994, 62:4626-4631 (Pubitemid 24302000)
33. Keppler D, Decker K: Studies on the mechanism of galactosamine- 1-phosphate and its inhibition of UDP-glucose pyrophosphorylase. Eur J Biochem 1969, 10:219-225
34. Keppler D, Lesch R, Reutter W, Decker K: Experimental hepatitis induced by D-galactosamine. Exp Mol Pathol 1968, 9:279-290
35. Record CO, Alberti KG, Williamson DH: Metabolic studies in experimental liver disease resulting from D(+)-galactosamine administration. Biochem J 1972, 130:37-44
36. Silverstein R: D-galactosamine lethality model: scope and limitations. J Endotoxin Res 2004, 10:147-162 (Pubitemid 38877735)
37. Miethke T, Wahl C, Heeg K, Echtenacher B, Krammer PH, Wagner H: T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med 1992, 175:91-98
38. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E; Soluble TNF Receptor Sepsis Study Group: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996, 334:1697-1702 (Pubitemid 26193621)
39. Seth A, Stern LJ, Ottenhoff TH, Engel I, Owen MJ, Lamb JR, Klausner RD, Wiley DC: Binary and ternary complexes between T-cell receptor, class II MHC and superantigen in vitro. Nature 1994, 369:324-327 (Pubitemid 24159543)
40. Rajagopalan G, Sen M, David CS: In vitro and in vivo evaluation of staphylococcal superantigen peptide antagonists. Infect Immun 2004, 72:6733-6737 (Pubitemid 39425463)
41. Rajagopalan G, Smart MK, Marietta EV, David CS: Staphylococcal enterotoxin B-induced activation and concomitant resistance to cell death in CD28-deficient HLA-DQ8 transgenic mice. Int Immunol2002, 14:801-812 (Pubitemid 34814641)
42. Rajagopalan G, Smart MK, Cheng S, Krco CJ, Johnson KL, David CS: Expression and function of HLA-DR3 and DQ8 in transgenic mice lacking functional H2-M. Tissue Antigens 2003, 62:149-161 (Pubitemid 36986599)
43. Rajagopalan G, Smart MK, Krco CJ, David CS: Expression and function of transgenic HLA-DQ molecules and lymphocyte development in mice lacking invariant chain. J Immunol 2002, 169:1774-1783 (Pubitemid 34857637)
44. Sriskandan S, Unnikrishnan M, Krausz T, Dewchand H, Van Noorden S, Cohen J, Altmann DM: Enhanced susceptibility to superantigenassociated streptococcal sepsis in human leukocyte antigen-DQ transgenic mice. J Infect Dis 2001, 184:166-173 (Pubitemid 32614045)
45. DaSilva L, Welcher BC, Ulrich RG, Aman MJ, David CS, Bavari S: Humanlike immune response of human leukocyte antigen-DR3 transgenic mice to staphylococcal enterotoxins: a novel model for superantigen vaccines. J Infect Dis 2002, 185:1754-1760 (Pubitemid 34615469)
46. Roy CJ, Warfield KL, Welcher BC, Gonzales RF, Larsen T, Hanson J, David CS, Krakauer T, Bavari S: Human leukocyte antigen-DQ8 transgenic mice: a model to examine the toxicity of aerosolized staphylococcal enterotoxin B. Infect Immun 2005, 73:2452-2460 (Pubitemid 40470848)
47. Welcher BC, Carra JH, DaSilva L, Hanson J, David CS, Aman MJ, Bavari S: Lethal shock induced by streptococcal pyrogenic exotoxin A in mice transgenic for human leukocyte antigen-DQ8 and human CD4 receptors: implications for development of vaccines and therapeutics. J Infect Dis 2002, 186:501-510 (Pubitemid 34876259)
48. Rajagopalan G, Iijima K, Singh M, Kita H, Patel R, David CS: Intranasal exposure to bacterial superantigens induces airway inflammation in HLA class II transgenic mice. Infect Immun 2006, 74:1284-1296 (Pubitemid 43185568)
49. Rajagopalan G, Sen M, Singh M, Murali N, Nath KA, Iijima K, Kita H, Leontovich AA, Unnikrishnan G, Patel R, David CS: Intranasal exposure to staphylococcal enterotoxin b elicits an acute systemic inflammatory response. Shock 2006, 25:647-656 (Pubitemid 44297027)
50. Rajagopalan G, Tilahun AY, Asmann YW, David CS: Early gene expression changes induced by the bacterial superantigen, staphylococcal enterotoxin B and its modulation by a proteasome inhibitor. Physiol Genomics 2009, 37:279-293 [Epub ahead of print March 2009]
51. Cheng S, Smart M, Hanson J, David CS: Characterization of HLA DR2 and DQ8 transgenic mouse with a new engineered mouse class II deletion, which lacks all endogenous class II genes. J Autoimmun 2003, 21:195-199 (Pubitemid 37410109)
52. Voll RE, Jimi E, Phillips RJ, Barber DF, Rincon M, Hayday AC, Flavell RA, Ghosh S: NF-kappa B activation by the pre-T cell receptor serves as a selective survival signal in T lymphocyte development. Immunity 2000, 13:677-689
53. Wang Q, Fang CH, Hasselgren P-O: Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice. Am J Physiol Regul Integr Comp Physiol 2001, 281:R1013-R1023
54. Nemzek JA, Xiao HY, Minard AE, Bolgos GL, Remick DG: Humane endpoints in shock research. Shock 2004, 21:17-25
55. Rajagopalan G, Asmann YW, Lytle AK, Tilahun AY, Theuer JE, Smart MK, Patel R, David CS: Cyclooxygenastic inhibition in superantigen-induced toxic shock. Shock 2008, 30:721-728
56. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R: In vivo imaging of NF-B activity. J Immunol 2002, 168:1441-1446
57. Galanos C, Freudenberg MA, Reutter W: Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 1979, 76:5939-5943 (Pubitemid 10216692)
58. Harmeet M, Gregory JG, John JL: Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 2006, 43:S31-S44
59. Wullaert A, Heyninck K, Beyaert R: Mechanisms of crosstalk between TNF-induced NF-kappa B and JNK activation in hepatocytes. Biochem Pharmacol 2006, 72:1090-1101 (Pubitemid 44465843)
60. Andy W, Ben W, Sofie Van H, Veerle B, Bart De G, Peggy P, Peter S, El Karim B, Karen H, Claude L, Rudi B: Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality. Hepatology 2005, 42:381-389
61. Bahjat FR, Dharnidharka VR, Fukuzuka K, Morel L, Crawford M, Clare-Salzler MJ, Moldawer LL: Reduced susceptibility of nonobese diabetic mice to TNF-alpha and D-galactosamine-mediated hepatocellular apoptosis and lethality. J Immunol 2000, 165:6559-6567
62. Mignon A, Rouquet N, Fabre M, Martin S, Pagès JC, Dhainaut Jean F, Kahn A, Briand P, Joulin V: LPS challenge in D-galactosamine- sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock. Am J Respir Crit Care Med 1999, 159:1308-1315 (Pubitemid 29202572)
63. Silverstein R, Norimatsu M, Morrison D: Fundamental differences during gram-positive versus gram-negative sepsis become apparent during bacterial challenge of D-galactosamine-treated mice. J Endotoxin Res 1997, 4:173-181 (Pubitemid 27356294)
64. Benjamin MA, Lu J, Donnelly G, Dureja P, McKay DM: Changes in murine jejunal morphology evoked by the bacterial superantigen Staphylococcus aureus enterotoxin B are mediated by CD4+ T cells. Infect Immun 1998, 66:2193-2199 (Pubitemid 28194120)
65. McKay DM, Benjamin MA, Lu J: CD4+ T cells mediate superantigeninduced abnormalities in murine jejunal ion transport. Am J Physiol 1998, 275:G29-G38 (Pubitemid 28374670)
66. Stone RL, Schlievert PM: Evidence for the involvement of endotoxin in toxic shock syndrome. J Infect Dis 1987, 155:682-689 (Pubitemid 17052990)
67. Liu SF, Malik AB: NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006, 290:L622-L645 (Pubitemid 43738989)
68. Hietbrink F, Besselink MG, Renooij W, de Smet MB, Draisma A, van der Hoeven H, Pickkers P: Systemic inflammation increases intestinal permeability during experimental human endotoxemia. Shock 2009, 32:374-378
69. Fink MP, Delude RL: Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. Crit Care Clin 2005, 21:177-196 (Pubitemid 40386748)